menu
    • menu

    Company profile for Ultimovacs

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mod...
    Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    UltimovacsNorway Flag
    Country
    Country
    Norway
    Address
    Address
    Ullernchausséen 64 0379 Oslo
    Telephone
    Telephone
    +47 413 80 080
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ultimovacs.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ultimovacs ASA: Approval and publication of prospectus
    Ultimovacs ASA: Approval and publication of prospectus

    28 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/28/3034754/0/en/Ultimovacs-ASA-Approval-and-publication-of-prospectus.html

    GLOBENEWSWIRE
    28 Feb 2025
    Share Share
    Ultimovacs ASA: Cancellation of subsequent repair offering
    Ultimovacs ASA: Cancellation of subsequent repair offering

    13 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/13/3026086/0/en/Ultimovacs-ASA-Cancellation-of-subsequent-repair-offering.html

    GLOBENEWSWIRE
    13 Feb 2025
    Share Share
    Ultimovacs ASA Reports Q4 2024 Financial Results & Update
    Ultimovacs ASA Reports Q4 2024 Financial Results & Update

    31 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/31/3018543/0/en/Ultimovacs-ASA-Reports-Fourth-Quarter-2024-Financial-Results-and-Provides-General-Business-Update.html

    GLOBENEWSWIRE
    31 Jan 2025
    Share Share
    Ultimovacs ASA: Invitation to Q4 2024 results webcast presentation
    Ultimovacs ASA: Invitation to Q4 2024 results webcast presentation

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015295/0/en/Ultimovacs-ASA-Invitation-to-fourth-quarter-2024-results-webcast-presentation.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Ultimovacs ASA: Notification of major holdings
    Ultimovacs ASA: Notification of major holdings

    09 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/09/3006900/0/en/Ultimovacs-ASA-Notification-of-major-holdings.html

    GLOBENEWSWIRE
    09 Jan 2025
    Share Share
    Ultimovacs ASA Extraordinary General Meeting held on Jan 9, 2025
    Ultimovacs ASA Extraordinary General Meeting held on Jan 9, 2025

    09 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/09/3006834/0/en/Ultimovacs-ASA-Extraordinary-General-Meeting-held-on-January-9-2025.html

    GLOBENEWSWIRE
    09 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search